HMGB1 and neoplasm: In a multivariate analysis of 71 patients undergoing sorafenib treatment, these investigators identified high-level expression of HMGB1 at four weeks (p = 0.001), high AFP at baseline (p = 0.025), tumor liver occupying rate (p = 0.009) and modified response evaluation in solid tumors [RECIST (p = 0.0001)] as independent predictors of poor overall survival [182].